Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.43 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 3/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 2/20 | 0.39 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15646433 | 0.82 | PARP10 (0.52) | KMT2AACACBACACA | |
| SCHEMBL29162043 | 0.77 | ALDH1A1 (0.40) | XDHALDH1A1KDM4EALOX15HSD17B10 | |
| SCHEMBL15505042 | 0.77 | XDH (0.50) | XDHALDH1A1KDM4EALOX15HSD17B10 | |
| SCHEMBL185428 | 0.77 | KDM4E (0.52) | ALDH1A1KDM4EALOX15HSD17B10HCAR3 | |
| SCHEMBL841924 | 0.76 | MAPT (0.62) | KMT2AXDHALDH1A1HSD17B10HCAR3 | |
| SCHEMBL26151730 | 0.75 | HPGDS (0.44) | MAPTACACBACACA | |
| SCHEMBL370174 | 0.74 | ACACB (0.37) | ALDH1A1RXRAACACBACACA | |
| SCHEMBL186124 | 0.73 | MAPT (0.59) | ALDH1A1KDM4EALOX15HSD17B10HCAR3 | |
| SCHEMBL17078037 | 0.73 | GCK (0.50) | ALDH1A1KDM4EALOX15HSD17B10P4HTM | |
| SCHEMBL8883301 | 0.73 | XDH (0.49) | KMT2AXDHALDH1A1HCAR3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101687860-A | Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB | 2010-03-31 | — | — | CN | claimed |
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | claimed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | claimed |
| EP-2158198-B1 | N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2013-03-20 | — | — | EP | disclosed |
| EP-2158198-B1 | N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2013-03-20 | — | — | EP | disclosed |
| US-20120238579-A1 | New Compounds 806 | BESIDKI YEVGENI (SE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238579-A1 | New Compounds 806 | BESIDKI YEVGENI (SE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238579-A1 | New Compounds 806 | BESIDKI YEVGENI (SE) | 2012-09-20 | — | — | US | disclosed |
| CN-101687860-B | Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| CN-101687860-A | Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB | 2010-03-31 | — | — | CN | disclosed |
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRL1, OPRK1, OPRD1 | KMT2A 2512/4885XDH 1382/4885ALDH1A1 854/4885 |
| US-20120238579-A1 | New Compounds 806 | CYP2B6, CYP11B2, NDUFS6 | KMT2A 3949/4885XDH 260/4885ALDH1A1 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.